Using Rituximab to treat severe aplastic anemia with platelet transfusion issues

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of rituximab in patients suffering from severe aplastic anemia (SAA) who experience platelet transfusion refractoriness (PTR). The study aims to provide a new treatment option for these patients, who currently face challenges with existing therapies. Participants will receive rituximab at a dosage of 100mg weekly for four weeks. The goal is to establish a safe and effective treatment method that is also cost-efficient.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Initial diagnosed SAA with PTR
* Age\>18 years old, regardless of gender
* Initial diagnosed SAA with PTR
* Age\>18 years old, regardless of gender

Exclusion Criteria:

* Allergy to rituximab
* Severe active infection
* Hypogammaglobulinemia
* Pregnant and lactating women
* Heart failure (NYHA classification IV)
* Individuals with epilepsy, dementia, and other mental disorders that require medication treatment who cannot understand or follow the research protocol
* Chronic infections or other chronic diseases that may be risk to the experiment
* The researchers believe that it is not suitable for participants

Where it's running

• Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Principal investigator: Huang Jinbo, MD. — Chinese Academy of Medical Sciences
• Study coordinator: Huang Jinbo, MD.
• Email: huangjinbo@ihcams.ac.cn
• Phone: +86 22 23909023

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Chidamide, Lenalidomide, and Rituximab as induction therapy for newly diagnosed elderly or unfit double-expressor DLBCL

  This trial tests whether the combo of chidamide, lenalidomide, and rituximab can help treat newly diagnosed double-expressor DLBCL in people who are elderly or not fit for standard chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07884708

• Rituximab plus Cyclosporine for Primary Membranous Nephropathy

  This study tests whether adding Cyclosporine to Rituximab helps people with primary membranous nephropathy achieve remission of heavy protein in the urine faster.

  Recruiting Phase 2/3 Peking University First Hospital · Beijing · NCT07861204

• Glofitamab combo vs Rituximab combo with chemo for relapsed/refractory DLBCL

  This study tests whether glofitamab with chemotherapy (JS203-GemOx) helps patients with relapsed or refractory DLBCL more than rituximab with chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT07808827

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

• Tafasitamab and Rituximab for newly diagnosed follicular lymphoma

  This study tests a combination of tafasitamab and rituximab to treat adults with newly diagnosed follicular lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07731789

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.